Vanguard Capital Management’s Aptevo Therapeutics APVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$23.1K Hold
12,713
– – ﹤0.01% 3970
2026
Q2
$56.4K Hold
12,713
– – ﹤0.01% 3927
2026
Q1
$54.3K Buy
+12,713
New +$87K ﹤0.01% 3912

Other funds holding APVO

Vanguard Capital Management's APVO Position: Q3 2026 in Review

Vanguard Capital Management held its Aptevo Therapeutics (APVO) position steady in Q3 2026 at 12,713 shares worth $23.1K. The position accounts for ﹤0.01% of the portfolio, ranked #3970.

Vanguard Capital Management first reported a position in APVO in Q1 2026 and has held it in 3 quarters since. The position peaked at $56.4K in Q2 2026. 11 funds tracked by Wall St. Rank hold APVO as of Q3 2026.

  • Vanguard Capital Management held 12,713 shares of Aptevo Therapeutics worth $23.1K as of Q3 2026.
  • Vanguard Capital Management left its Aptevo Therapeutics share count unchanged in Q3 2026.
  • Aptevo Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3970 holding.
  • Vanguard Capital Management first reported a position in Aptevo Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Aptevo Therapeutics position peaked at $56.4K in Q2 2026.
  • 11 funds tracked by Wall St. Rank held Aptevo Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.